Advanced Medical Solutions Group Regulatory News (AMS)

11 September 2015

Advanced Medical Solutions Group plc

("AMS" or the "Group")

DIRECTORS' SHAREHOLDINGS

Advanced Medical Solutions Group plc (AIM:AMS), the global medical technology company, announces that the Board, following a recommendation from the Remuneration Committee, has granted new share options to the following Directors under the Advanced Medical Solutions Long Term Incentive Plan (the 'LTIP') on 10 September 2015. The vesting period of these options is subject to certain performance criteria over a 3 year period.

- Ends -

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc - see www.admedsol.com 

AMS is a world-leading independent developer and manufacturer of innovative and technologically advanced products for the global surgical, wound care and wound closure markets, focused on quality outcomes for patients and value for payors. AMS has a wide range of products that include silver alginates, alginates, foams, tissue adhesives, sutures and haemostats, which it markets under its brands ActivHeal®, LiquiBand® and RESORBA® as well as supplying under white label.

AMS's products, manufactured out of two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic, are sold in 65 countries via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. Established in 1991, the Group has approximately 470 employees. For more information please see www.admedsol.com.